甲状腺乳头状癌雌激素受体α36的表达及其临床意义

Expression of ERα36 in papillary thyroid carcinoma and its correlation with clinical features

目的：测定雌激素受体α36（ERα36）在甲状腺乳头状癌（PTC）原发灶中的表达,探讨其临床意义.方法：免疫组织化学显色检测ERα36和ERα66在PTC组织中的表达.结果：PTC组织中,ERα36和ERα66均特异性表达于肿瘤细胞,ERα36表达水平高于ERα66（67.6％vs 20.6％）;45岁以上患者ERα36阳性率高于45岁以下患者（95.2％ vs 55.3％）.PTC组织中ERα36和ERα66的表达与性别、淋巴结转移情况无关.结论：ERα36与PTC密切相关,较ERα66更有可能在PTC发生与发展中发挥重要作用.

Objective： To investigate the expression of estrogen receptor α 36（ERα36） in thyroid papillary carcinoma （PTC） and its correlation with clinical features. Methods： ERα36 and ERα66 were examined in the specimens of PTC by using the method of immunohistochemistry. Results： The expression of ERα36 was significantly higher than that of ERα66 （67.6% vs 20. 6%）; ERα36 positive patients aged over 45 years in PTC were higher than those aged less than 45 years （95.2% vs 55.3%）. The expression of ERα36 had no correlation with gender or lymph node metastasis. Coneluslon： ERα36 was extensively expressed in PTC and might play a more important role in its genesis and development compared with ERα66.